AlveoGene
Developing inhaled gene therapies for rare respiratory diseases such as alpha-1 antitrypsin deficiency.
- Biotech & Life Sciences
- Seed
- Oxford
- Sector
- Biotech & Life Sciences
- Stage
- Seed
- Based in
- Oxford
- Founded
- 2022
- Funding raised
- Undisclosed
- Website
- alveogene.com
AlveoGene develops inhaled gene therapies for rare respiratory diseases. It holds an exclusive licence to the InGenuiTy lentiviral delivery platform, built over more than a decade by the UK Respiratory Gene Therapy Consortium with around £72 million of grant funding, which is designed to give long-lasting gene expression in the lung and can be re-dosed. Its first candidate, AVG-001, aims to treat alpha-1 antitrypsin deficiency. The company was created by Oxford Science Enterprises, the Harrington Discovery Institute and the University of Edinburgh's Old College Capital together with six consortium scientists from Imperial, Oxford and Edinburgh.
Team
- Gerry McLachlan, Co-founder LinkedIn
More startups in the directory
Boone
Nutrition app that analyses meals from photos, barcodes and receipts, with optional DNA insights.
Vocavio
AI voice analytics that measure team communication performance in high-pressure training.
KIT-AR
Augmented reality and AI software that guides manufacturing workers to cut assembly errors and quality costs.
Entropyst
Electrified reactor technology that converts methane and ammonia into clean hydrogen and carbon materials.
InfraFund
Platform for tokenised investment in renewable energy projects, letting communities co-own local clean energy.
UGiftMe
Online platform for buying and sending digital gift cards and vouchers from 1,000+ brands, with a wallet to swap them.
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.